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Abstract:
Resveratrol is a polyphenol antioxidant found in red wine known to have anti-aging, anti-cancer,
and anti-obesity effects in both humans and animals. Resveratrol's primary biological action is
as an antioxidant, causing a reduction in reactive oxygen species (ROS). ROS are produced as
byproducts of normal metabolic functions, but become abnormally elevated in individuals who
consume a high fat diet (HFD) or who have metabolic conditions like Type II Diabetes Mellitus
(T2DM); in these circumstances, abnormal elevation in ROS leads to cellular damage and cell
death. Another common effect of a diet high in fat and calories is cognitive impairment:
specifically, impaired memory. Here, we tested the hypothesis that resveratrol might attenuate
memory impairment caused by the ingestion of a high fat diet. Animals on either a control
(chow) diet or high fat diet (60% kcal fat) were treated with resveratrol (or vehicle) once weekly
for 20 weeks. Although no metabolic effects of the resveratrol treatment were seen, HFD
animals treated with resveratrol performed significantly better in behavioral tasks, indicating a
possible role of resveratrol as a therapeutic intervention to improve memory in individuals with
metabolic dysregulation. Additionally, healthy rats treated with resveratrol demonstrated a
higher level of anxiety than their matched controls. Behavioral and metabolic measures were
complemented by post-mortem measurement of molecular markers linked to memory formation,
insulin signaling, and the cellular response to oxidative stress, intended to help elucidate
neuroprotective mechanisms of resveratrol. Ultimately, this study indicates a possible role for
resveratrol in preventative care for individuals prone to metabolic disease and related cognitive
dysfunction.

3

!
Acknowledgements:
The author would like to first acknowledge Dr. Ewan McNay for his unwavering
guidance, infinite support, and encouraging nature throughout the entirety of her time working in
his lab. She would also like to thank the Director of the Honors Program in Biology, Dr. Richard
Zitomer, for readily agreeing to act as a second reader for this work and his support throughout
her time here at the University at Albany. The author thanks Dr. Jeffrey Haugaard for providing
an environment that allowed the author to thrive both academically and professionally, driving
her to strive for excellence in class and in the lab. She would like to extend a great thank you to
Roi Ankawa, undergraduate research assistant in the McNay lab for working on this project
alongside her and providing guidance and support when she needed it most. She would like to
acknowledge additional current members of the McNay lab including Sean Smith and Julia
Bataille and former members Dr. Danielle Osborne, Alvin George, Dennis Fitzgerald, Brian
Anderson, and Michael Vidal for their encouragement and friendship. Additionally, she would
like to thank Dr. Kim DeWeerd, the Director of the Molecular Core in the Life Sciences
Research Building and Dr. Antigone McKenna, the veterinarian for the animal facility. Finally,
the author would like to acknowledge and truly thank her parents, family, friends, and her better
half, Kevin Schordine, for always being there when she needed it most.

4

!
Table of Contents

Title Page………………………………………………………………………………….1
Advisor/Committee Recommendation…………………………………………………….2
Abstract……………………………………………………………………………………3
Acknowledgements………………………………………………………………………..4
Table of Contents………………………………………………………………………….5
Text of Thesis
Introduction………………………………………………………………………..6
Materials and Methods…………………………………………………………….9
Results……………………………………………………………………………14
Discussion………………………………………………………………………..24
References………………………………………………………………………..31

5

!
Introduction:
Obesity continues to increase in prevalence. It currently ranks third in leading causes of
preventable deaths in the US, behind smoking and high blood pressure, respectively (Danaei et
al., 2009). Obesity may arise from a variety of lifestyle factors, including inactivity, poor dietary
habits, and stress; many individuals who are obese consume a diet high in saturated fat, simple
sugars, and salt. If left unchecked, obesity can lead to inflammation and oxidative stress that may
compromise an already unstable system. In particular, a diet rich in fat causes significantly
increased production of reactive oxygen species (ROS) through excess lipid peroxidation and
altered oxygen metabolism (Fernández-Sánchez, 2011). These ROS can lead to damage and may
contribute to the development of insulin resistance, type II diabetes, cancer, and heart disease.
Besides various physiological health risks, ingesting a high fat diet (HFD) also results in
severe cognitive impairment, specifically in spatial memory tasks governed by the hippocampus
(Kanoski & Davidson, 2011). The hippocampus is extremely sensitive to metabolic changes and
ROS, making it vulnerable to the effects of systemic obesity (Winocur & Greenwood, 2005).
Besides changing diet and increasing daily physical activity, treatments for obesity may need to
focus on reducing ROS in order to reduce the amount of damage, cognitive impairment, and risk
of subsequent disease states.
Resveratrol (3,4,5-trihydroxy-trans-stilbene) is a polyphenol antioxidant found in red
wine that has potent effects on many different body systems. It has been proposed as a possible
treatment for cancer, cardiovascular disease (Lin & Tsai, 1999), and ischemic injury due to
stroke (Simão et al., 2012). It has also been thrust into the media and clinical spotlight because
of its apparent anti-aging and anti-angiogenic effects (Kasiotis, Pratsinis, Kletsas, &
Haroutounian, 2013). In addition to a role in regulation of vascular supply, resveratrol is also of
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interest as a potential therapeutic intervention for patients with metabolic diseases that may cause
abnormally elevated oxidative stress, such as obesity. In these patients, the potential role of
resveratrol would be to reduce oxidative stress, which may be especially effective in obese, aged
individuals.
Resveratrol is able to ameliorate several causes of metabolic stress and dysfunction, but
the exact molecular mechanisms behind its beneficial effects remain unknown. Specifically,
resveratrol has been shown to protect against diet-induced obesity and systemic insulin
resistance, improving both glycemic control through the AMPK pathway (Do et al., 2012) and
insulin sensitivity by reducing oxidative stress and improving Akt signaling (Bransyó et al.,
2011). It has also been shown to induce both the deacetylation and total expression of PGC-1α, a
transcription factor involved in the regulation of gluconeogenesis and cellular metabolism,
through activation of SIRT1 (Lagouge et al., 2006). All of these mechanisms may contribute to
the renormalization of metabolism in obese individuals and reduction of overall oxidative stress.
In addition to regulation of glucose metabolism, resveratrol has been shown to improve
memory and ameliorate cognitive deficits that accompany metabolic and neurodegenerative
disorders. Resveratrol improved word memory and reduced body fat in overweight humans
(Witte et al., 2014). Additionally and more specifically, resveratrol was found to modulate
molecules that participate in learning and memory and long-term potentiation (LTP): Zhao et al.
showed that resveratrol treatment improved learning and memory formation and LTP induction
in the hippocampi of mice via pathways involving reduced micro-RNA levels and increased
CREB expression as well as brain-derived neurotrophic factor synthesis (Zhao et al., 2013). In
hippocampal slices, evidence suggests that resveratrol may play a role in reducing glutamatergic
excitotoxicity induced by overactivation and overexpression of NMDA and AMPA receptors
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(Quincozes-Santos, 2014), which can occur in metabolic disorders including type 2 diabetes
mellitus (Trudeau, Gagnon, & Massicotte, 2004) and neurodegenerative disorders such as
Alzheimer’s disease (Felice, 2013).
Thus, several studies support a therapeutic potential for resveratrol to ameliorate
cognitive deficits due to metabolic disorders. While these studies provide promising results,
many of them have been conducted in vitro or in isolated animal models and the exact
mechanisms by which resveratrol acts remain unknown. Additionally, many previous studies
have examined the effects of resveratrol on molecular cascades in the periphery, such as
reducing IGF-1 levels and corresponding insulin signaling in the liver (Baur et al., 2006) or
increasing oxidative capacity and fatty acid oxidation by upregulating the transcription of related
genes MCAD and UCP-3 in muscle (Lagouge et al., 2006). These studies fail to investigate
specific mechanisms in the brain.
By administering a high fat diet in conjunction with weekly injections of resveratrol, this
project aimed to identify the exact molecular effects of resveratrol in the brain, specifically in the
hippocampus. It was hypothesized that resveratrol treatment would ameliorate both the cognitive
and metabolic deficits associated with a high fat diet. At the end of a twenty-week period, rats
underwent a battery of cognitive tasks to assess the effects of resveratrol administration on
specific cognitive regions in the brain. By comparing performance on behavioral tasks to levels
of hippocampal receptors, transporters, and signal transducers, this project ultimately aimed to
determine the mechanisms by which resveratrol acts both in the periphery and the brain.
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Materials and Methods:
Animals
All procedures were approved by the Institutional Animal Care and Use Committee at the
University at Albany. Forty Sprague-Dawley rats (Charles River, Wilmington, MA) were
purchased at six weeks of age and doubly housed on a 12-hour light/dark schedule (lights on at
7:00am). After one week of acclimation, rats were randomly selected to receive regular Purina
Chow diet (control; 3.35 kcal/g) or a diet consisting of 60% kcal from fat (D12492, Research
diets, Inc.) (high fat diet; 5.24 kcal/g) and given ad libitum access to food and water. Rats were
maintained on their respective diets for 21 weeks until euthanasia by decapitation.
Resveratrol Administration
Rats were pseudorandomly assigned to receive weekly injections of resveratrol or
vehicle, creating four groups of animals in a 2x2 diet x treatment factorial design. Rats assigned
to the resveratrol groups were injected at a dose of 20mg/kg. Injections continued once weekly
for 20 weeks. Animals were handled immediately prior to injections and also at an additional
time point during each week to ensure the animals were comfortable in the presence of the
experimenters.
Food Weights
Food weights were measured biweekly to monitor food intake. The food in each cage was
replenished and the total weight of the food and the metal food dispenser was determined. After
24 hours, food was removed from the cages and weighed again and the difference between the
two measurements was calculated, indicating the amount of food ingested by both animals over
the 24-hour period since rats were doubly housed throughout the duration of the project. Caloric
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intake per cage was also monitored throughout the project. No data were collected on the feeding
activity of individual animals.
Behavioral Testing
The testing apparatus was thoroughly cleaned with 70% EtOH at the beginning and in
between each animal and allowed time to dry. Behavioral testing occurred over the course of five
days. At the end of each testing trial, animals were returned to their home cage.
Day 1: Open Field
Animals were tested on the open field task as a measure of anxiety. Methods were
adapted from Rogers et al. (1999). The open field appraratus consists of an open field arena (76
x 57 x 35 cm) divided into 16 squares with 12 on the periphery and 4 in the middle. Behavioral
data were collected by an observer blind to the condition of experimental animals. Each rat was
placed in the apparatus for 5 minutes and allowed to explore the apparatus freely. Time spent in
the center zone was measured and used as an indicator of anxiety, with less time spent in the
center zone indicative of higher levels of anxiety.
Day 1 and 2:Novel Object Recognition
Memory was tested with a novel object recognition task. Methods were adapted
(Antunes, & Biala, 2012) and subjects were placed in the open field arena in the presence of two
identical objects. Each rat was placed in the apparatus for 5 minutes and allowed to explore the
apparatus and the objects for training. Time spent with both objects was measured during testing
to ensure no preference between right or left identical objects. Followed by a 24-hour inter-trial
interval, one object was replaced with one of a different shape, color, and texture and again rats
were allowed to explore for 5 minutes. Time spent with each object was also measured during
testing to compare time spent with the novel object with the time spent with the old object. A
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larger percentage of time spent with the novel object during the testing period was interpreted as
superior memory. All objects were sanitized with 70% EtOH between each animal.
Day 3: Spontaneous Alternation
Spatial working memory was quantified by the use of the spontaneous alternation task.
Methods were adapted from McNay et al., 2010. A 4-arm plus-maze was used. Animals were
placed into the center of the maze always facing the same arm and allowed to explore freely for
20 minutes before being removed and returned to their holding chamber. The order of arm
entries was recorded for later analysis. Alternation is defined as entry into all four arms within a
five-arm entry period.
Day 4 and 5: Conditioned Contextual Fear (CCF)
Finally, hippocampally-dependent conditioned contextual fear was measured. Methods
were adapted (Johansen, Cain, Ostroff, & LeDoux, 2011) and initially, rats were placed in a
chamber with distinct spatial cues. Following a 30-second habituation period, a tone sounded
(5kHz) for 10 seconds and was followed immediately by five seconds of 0.8mA footshock. This
was repeated three times with one-minute inter-trial intervals. Rats were returned to their
homecage until testing 24 hours later when they were returned to the same context for three
minutes, with the amount of time spent freezing recorded. More time spent freezing is
interpreted as better memory of the fearful context.
Glucose Tolerance Test and Insulin Tolerance Test
Blood glucose was measured every two weeks. Animals were fasted for one hour prior to
testing. Blood was obtained by tail-prick and measured using a blood glucose meter (OneTouch
Ultra Mini Monitor). A glucose tolerance test was performed on each animal one week before
behavioral testing. Animals were fasted for one hour and then administered an intra-peritoneal
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(I.P.) injection of 1g/kg body weight D-(+)-glucose (Sigma-Aldrich, G8270), dissolved at
concentration of 0.5g/mL in dH2O . Blood glucose was measured using a blood glucose meter at
0 minutes (baseline, prior to glucose injection), 30 minutes after injection, 60 minutes after
injection, and 120 minutes after injection.
An insulin tolerance test was also performed on each animal one week before behavioral
testing, 6 hours after the glucose tolerance test. Initial blood glucose was measured and human
insulin was immediately injected at a dose of 6U/kg. Blood glucose was measured at 0 minutes
(baseline, prior to insulin injection), 30, 60, 120, and 180 minutes after injection. If at any point a
subject’s blood glucose dipped below 30mg/dl, their individual test was terminated and they
were treated with an appropriate injection of glucose solution.
Tissue, Trunk Blood, and Epididymal Fat Pad Collection
The day following completion of behavioral testing, animals were killed by decapitation
following anesthesia by isoflurane. Several brain regions were collected, including the pituitary
gland, hypothalamus, sections of the prefrontal cortex, and the hippocampus. Each side of the
dorsal hippocampus was dissected out and immediately processed for western blotting. Samples
dissected from the periphery included fat, leg muscle, and samples from the stomach wall, liver,
pancreas, and adrenal glands. All tissue samples were frozen on dry ice immediately after
collection. Trunk blood was also collected, spun down at 2500 rpm for 10 minutes, and the
serum fraction was collected for analysis. Epididymal fat pads were harvested from the carcass
and weighed following trunk blood collection.
Western Blotting
Each side of the dorsal hippocampus was dissected out and immediately processed for
western blotting. Both sides were homogenized together with 300uL of homogenization buffer
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(BioVision) containing protease inhibitor (1:500) (BioVision) from which 30uL of homogenate
was removed and combined with 200uL of RIPA buffer containing a protease and phosphatase
inhibitor cocktail (1:200) (ThermoScientific). Initial homogenate was processed according to
manufacturer’s instructions (BioVision) to isolate plasma membrane fractions from the total
sample.
All samples then underwent protein quantification using a BCA assay kit and
manufacturer’s instructions were followed (Pierce Scientific). Using the data from the BCA
assay, samples were mixed with 2x Laemmli sample buffer (BioRad) with 5% 2mercaptoethanol to achieve optimal sample amounts for total (20ug) and plasma membrane
(5ug) samples. Total samples were heated in boiling water for 4 minutes prior to loading. Plasma
membrane samples were not heated. All protein samples were loaded into pre-cast SDS-PAGE
10% gels (BioRad) along with biotinylated ladder. Gels were run at 240V for 15 minutes and
then 190V until the dye ran off the bottom of the gels (approximately 45 minutes). Once
finished, the gels were transferred to PVDF membranes at 4oC for 1 hour. Membranes were
removed and rinsed three times in TTBS and then blocked in 5% milk in TTBS.
Primary antibodies were incubated overnight at 4oC for pAMPAR (Ser 845) GluR1 (Cell
Signaling; 1:1000), AMPAR GluR3 (Cell Signaling; 1:1000), pAkt (Ser 473) (Cell Signaling;
1:2000), Akt (Cell Signaling; 1:1000), pAMPK (Thr172) (Cell Signaling; 1:1000), AMPK (Cell
Signaling; 1:1000), CREB (Cell Signaling; 1:750), GluT4 (Millipore; 1:1000), PGC-1α (Abcam;
1:1000), NMDAR2B (Cell Signaling; 1:1000), or Nrf2 (Cell Signaling; 1:1000). After rinsing
three times with TTBS, membranes were incubated in the species-appropriate biotinylated
secondary antibodies at 1:10,000 in TTBS for one hour at 25oC. Once again, blots were rinsed
three times with TTBS and incubated in tertiary HRP-streptavidin in 5% milk in TTBS for one
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hour at 25oC. Membranes were rinsed three times with TTBS and twice with TBS, after which
chemiluminescent (ThermoScientific) was applied and the blots were imaged using a BioRad
ChemiDoc XRS imager. Bands were analyzed using NIH free ImageJ software.
Data Analysis
All statistical analyses were performed with Graphpad Prism 6 software. All results are
depicted as mean + SEM and significance was set at a<0.05. Both two-way ANOVAs and twoway repeated measures ANOVAs were used, with post hoc differences determined by specific
planned comparisons using Bonferroni tests on the ANOVA analyses. Data points two standard
deviations or more away from the mean were excluded. All abbreviations during data analysis
are as follows: C/V—chow diet and vehicle injected; C/RSV—chow diet and resveratrol
injected; HFD/V—high fat diet and vehicle injected; HFD/RSV—high fat diet and resveratrol
injected.
Results
Resveratrol had no effect on body weight, food intake, or blood glucose
Body weights were measured once weekly throughout the experiment. As seen in Fig. 1,
resveratrol had no impact on body weight. Both groups sustained on the high fat diet weighed
significantly more than the groups fed the regular chow diet (p<0.05), but there was no
difference in weight between the two high fat diet groups or the two chow groups. This is also
shown in the post-mortem epididymal fat pad weights (Fig. 2). Resveratrol had no effect on fat
pad weights, but diet had a significant effect (p<0.05) on fat composition.
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*

Figure 1: Body weights measured weekly over the course of 20 weeks. Diet had a significant
main effect on weight gain, but resveratrol treatment had no effect. (*p<0.05) n=10 per group.

*

Figure 2: Epididymal fat pad weights, measured at euthanasia. There was a main effect of diet on
epididymal fat pad mass, while treatment had no effect. (*p<0.05) n=10 per group.
Neither resveratrol nor diet had no effect on fasting blood glucose throughout the duration of the
diet-treatment paradigm (Fig. 3).
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Figure 3: Blood glucose levels measured biweekly. No significant effect of diet or treatment was
found. n=10 per group.
There was a significant effect of diet on food intake throughout the duration of the project:
animals fed the high fat diet, regardless of treatment, ingested significantly less food than rats fed
the control diet (Fig. 4a). However, there was no effect of diet or treatment on total caloric intake
(Fig. 4b).
a.

b.

*

Figure 4: a. Food intake per cage measured biweekly. Those fed the control chow diet ate
significantly more food than subjects fed the high fat diet. (*p<0.05) n=10 per group.
b. Caloric intake per cage. No significant effects of diet or treatment were found. n=10 per group.
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Additionally, the glucose tolerance test (Fig. 5a) and insulin tolerance tests (Fig. 5b) did not
reveal any significant patterns or differences in glucose metabolism due to diet or treatment.
a.

b.

Figure 5: a. Results of glucose tolerance test. Blood glucose was tested at t=0 (baseline), 30, 60,
and 120 minutes post-injection. No significant effects were found. n=10 per group.
b. Results of insulin tolerance test. Blood glucose was tested at t=0 (baseline), 30, 60, 120, and
180 minutes post-injection. No significant effects were found. n=8-10 per group.
Resveratrol and high fat diet modulate anxiety behavior
Rats were tested in an open field paradigm to measure anxiety behavior. Animals in the chowresveratrol administration group spent significantly less time in the center zone than their
matched controls. There was a significant interaction between the diet and treatment conditions
for the open field task (Fig. 6).
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Figure 6: Results of open field task. There was a significant interaction between diet and
treatment in the open field task resulting in significantly decreased time spent in the center zone
in the C/RSV and HFD/V groups. (*p<0.05) n=10 per group
Resveratrol has no effect on spatial working memory
Animals were tested on both the novel object recognition and spontaneous alternation task, both
used to test hippocampal memory processes. Neither resveratrol nor diet had an effect on novel
object recognition (Fig. 7a) or spontaneous alternation performance (Fig. 7b).
a.

b.

Figure 7: a. Results of novel object recognition task. No significant effects of diet or treatment
were found. n=10 per group.
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b. Results of spontaneous alternation task. No significant effects of diet or treatment were found.
n=10 per group.
Resveratrol improves contextual conditioned fear memory in rats fed a high-fat diet
In the contextual conditioned fear task, animals that were maintained on the high-fat diet
demonstrated decreased freezing behavior, suggesting memory impairment due to the high fat
diet. However, when resveratrol was co-administered along with the high-fat diet, animals
performed comparably to controls given vehicle. In the contextual conditioned fear task,
resveratrol was able to ameliorate cognitive deficits initially caused by the high-fat diet (Fig. 8).

*

*
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Figure 8: Results of conditioned contextual fear task. There was a significant interaction between
diet and treatment in this task. (*p<0.05) n=10 per group
Resveratrol and diet exert differential effects on molecular markers of memory and metabolism
In order to investigate the effects of diet and treatment on molecular markers of memory
and metabolism, western blotting of hippocampal homogenates was conducted with both total
and plasma membrane fractions. Blots were probed for total (T) amounts of pAkt/Akt,
pAMPAR/AMPAR, pAMPK/AMPK, CREB, GluT4, Nrf2, and PGC-1α and plasma membrane
(PM) amounts of AMPAR, NMDAR, and GluT4. All protein measures are reported as percent
control after being normalized to β-actin, unless otherwise specified.
19

!
A significant effect of diet was seen in total levels of Akt (Fig. 9a), but not in its
activated, phosphorylated form (Fig. 9b).
a.

b.

*

!
!!
!
Figure 9: a. Relative optic density of Akt:β-Actin. There was a significant main effect of diet on
Akt levels. (*p<0.05) n=10 per group.
b. Relative optic density of pAkt:Akt, both normalized to β-actin. A significant main effect of
diet was also found for pAkt. (p<0.05) n=10 per group.
No significant effects were seen in PGC-1α expression (Fig. 10)

Figure 10: Relative optic density of PGC-1α:β-Actin. No significant effects of diet or treatment
were observed with this target. n=10 per group.
Significant effects were seen in both levels of phosphorylated AMPAR (Fig. 11b) and total
AMPAR (Fig. 11c), but no effects were seen in levels of plasma membrane AMPAR (Fig 11a).
20
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a.

b.

*

c.

*

Figure 11: a. Relative optic density of AMPAR (PM): AMPAR (T), a measure of translocation to
the plasma membrane and therefore active presence in the synapse. Both normalized to β-actin.
No significant differences were seen between groups due to diet or treatment. n=10 per group
b. Relative optic density of pAMPAR:AMPAR, both normalized to β-actin. A significant main
effect of diet was present in the resveratrol-treated groups. (*p<0.05) n=10 per group
c. Relative optic density of AMPAR(T):β-Actin. A significant main effect of treatment was
found in the chow-fed groups. (*p<0.05) n=10 per group
There were no effects seen in either total levels of NMDAR (Fig. 12a) or amounts of NMDAR in
the plasma membrane (Fig. 12b).
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a.

b.

Figure 12: a. Relative optic density of NMDAR (PM):NMDAR (T), both normalized to β-actin.
No significant differences between groups were observed. n=10 per group
b. Relative optic density of NMDAR (T):β-Actin. A significant main effect of treatment was
found. (p<0.05) n=10 per group.
No effects of diet or treatment were seen in the transcription factor CREB (Fig. 13).

Figure 13: Relative optic density of CREB:β-Actin. No significant effects were found. n=10 per
group
Additionally, no significant effects were seen in the oxidative stress marker NrF2 (Fig. 14).
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Figure 14: Relative optic density of NrF2:β-Actin. No significant effects were found. n=10 per
group.
Total levels of AMPK showed no response to treatment or diet (Fig. 15a). However, pAMPK
demonstrated a robust interaction between the two variables, with pAMPK levels significantly
heightened in the C/RSV and HFD/V groups, but lower in the C/V and HFD/RSV groups (Fig.
15b).
a.

b.

*

*

!
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Figure 15: a. Relative optic density of AMPK:β-Actin. No significant effects were found. n=8
per group.
b. Relative optic density of pAMPK:AMPK, both normalized to β-Actin. A significant
interaction was found between diet and treatment in this target. (*p<0.05) n=8 per group.
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Total levels of GluT4 were subject to a significant interaction between diet and treatment (Fig.
16a), but there were no significant differences between groups in the plasma membrane fractions
(Fig. 16b), indicating that resveratrol or diet did not have an effect on the translocation and
therefore greater usage of GluT4.
a.

b.

*

*

Figure 16: a. Relative optic density of total GluT4:β-Actin. A significant interaction was found
between diet and treatment. (*p<0.05) n=10 per group
b. Relative optic density of GluT4 (PM): GluT4 (T), both normalized to β-Actin. No significant
results were found in this case. n=10 per group

Discussion
Administration of resveratrol alongside a high-fat diet over the course of 20 weeks
revealed interesting patterns in physiological responses and behavior. Unlike several studies that
provide evidence for resveratrol’s role in reducing weight gain while ingesting a high-fat diet
(Lagouge et al., 2006; Kim, Jin, Choi, & Park, 2011), we found no differences in weight between
HFD-fed rats treated with resveratrol and those given vehicle. The significant differences in
epididymal fat pad weight support the conclusion drawn from body weight measurements that
weight gain on a HFD was due to increased obesity, but resveratrol administration had no effect
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on weight gain or body fat content. Resveratrol also did not exert a metabolic effect on the blood
glucose levels of high fat diet rats as compared to their controls.
While resveratrol did not cause any significant changes in body weight, fat content, or
blood glucose, it did exert significant behavioral effects. Resveratrol administration to rats fed a
chow diet caused a significant decrease in time spent in the center zone during the open field
task, indicating a high level of anxiety as compared to its control. Additionally, HFD/V animals
also showed significantly heightened anxiety in this task. In the resveratrol treated groups, diet
had an effect on anxiety behavior, with the HFD/RSV animals demonstrating less anxiety
behavior than their chow-diet counterparts. Resveratrol did not have an effect on the behavior of
rats in the novel object recognition task or the spontaneous alternation task. This is surprising
because resveratrol has demonstrated the ability to affect performance on these tasks using an
identical dose (Anastácio, 2014).
In the conditioned contextual fear task, resveratrol treatment of high fat diet rats
ameliorated the deficit seen in HFD/V animals, and allowed the HFD/RSV cohort to perform at
levels comparable to controls. Previously, the open field task revealed resveratrol’s role as a
possible anxiety-inducing agent in the C/RSV group, which may have manifested itself in the
improvement in performance in the HFD/RSV group in the conditioned contextual fear task.
Future studies should address the exact mechanisms by which resveratrol moderates fear
memory in the hippocampus and how it possibly can be modulated by a change in diet.
These behavioral results, considering that resveratrol did not reduce weight gain in rats
fed a HFD, supports the hypothesis that resveratrol alone is responsible for the improved
performance of rats receiving the experimental treatment in the HFD condition. High fat diets are
associated with hippocampal dysfunction and therefore poor performance on related behavioral
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tasks (Kanoski & Davidson, 2011) and weight loss can attenuate this dysfunction (Miller et al.,
2013). It is clear that there is no significant difference in weight between the HFD/V and
HFD/RSV groups, supporting the claim that resveratrol treatment was responsible for the
improved performance of the HFD/RSV group on the CCF task.
The preliminary molecular results show some expected and unexpected patterns. Akt
levels were decreased in the high fat diet groups, which may be indicative of overall impaired
insulin signaling in both groups. No other group demonstrated a deficit in Akt levels and there
was no effect of diet or treatment on pAkt levels. There was no indication that levels of oxidative
stress were high in either of the high fat diet groups, contrary to original thought. Resveratrol or
diet also did not exert an effect on CREB, a surprising result since this has been demonstrated
before, albeit in a slightly different context (Zhao et al., 2013).
Resveratrol and diet both had differing effects on AMPAR activity and overall
expression. Phosphorylated AMPAR levels were significantly decreased in HFD/RSV rats
compared to C/RSV rats, indicating a main effect of diet on pAMPAR levels. AMPAR is
phosphorylated by PKA at serine 845 in its GluR1 subunit in order to increase its open
probability, and therefore become more active in the synapse (Banke, Bowie, Lee, Huganir,
Schousboe, & Traynelis, 2000). While pAMPAR levels were decreased due to high fat diet in the
resveratrol treated groups, overall AMPAR levels were significantly lower in C/RSV animals as
compared to their vehicle-treated controls, indicating a main effect of treatment. It is not clear if
this relationship has meaning in the context of the behavioral results, but future studies could
possibly elucidate this relationship and how it may result in the modulation of behavior.
Resveratrol increased pAMPK levels in the C/RSV group while diet seems to be the
primary cause of pAMPK activation in the HFD/V group. There was a strong interaction
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between diet and treatment for pAMPK. Resveratrol is a known AMPK activator (Patel, Gupta,
& Dey, 2011) and additionally is upregulated in a high-fat, high fuel state inducing glucose
usage and therefore energy production (Pellatt, Rice, & Mason 2011). The interesting effect in
this case is among the HFD/RSV group where, despite the fact that they are being treated with
resveratrol and being fed a high fat diet and should, according to the other groups, demonstrate
the highest level of pAMPK, their levels are comparable to controls. More research must be done
investigating the relationship between the diet and treatment and how it relates to AMPK
activation, especially in the HFD/RSV condition.
Total GluT4 levels also demonstrated an interaction between diet and treatment. Total
GluT4 levels were decreased in both the C/RSV and HFD/V groups as compared to C/V,
indicating that both resveratrol treatment and diet may have an effect on total GluT4 levels.
However, the amount of GluT4 found in the plasma membrane remained unaffected by treatment
or diet.
These behavioral and molecular effects may provide support for an inverted-U dose
effect of resveratrol in regards to metabolism. As indicated by the open field task, resveratrol
resulted in high levels of anxiety behavior in the C/RSV group, but caused no issues in the
HFD/RSV group. In the the CCF task, however, resveratrol supplementation aided the
HFD/RSV group in performing the task at comparable levels to controls and nonsignificantly
decreased performance in the C/RSV group. These results support a metabolically-dependent
model for resveratrol’s effects, where it is helpful when administered alongside a high fat diet
but detrimental when given with a healthy diet. This hypothesis is further supported by the
molecular results of pAMPK levels, which are significantly heightened in the C/RSV and
HFD/V groups, but at lower levels in the C/V and HFD/RSV groups. It has been postulated that
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overactivation of the AMPK pathway may lead to impairment of normal memory functions
(Dash, Orsi, & Moore, 2006), which may help explain why resveratrol treatment of chow-fed
rats seemed to be detrimental to their performance. Future studies should aim to parse out the
exact effects of resveratrol on anxiety and AMPK to explain the behavioral and molecular effects
seen in these two tasks.
The overall findings presented in this study are significant but require further
investigation in all areas before definitive conclusions can be drawn. An aspect of its lack of
strength is the failure of the molecular data to align with the observed behavioral effects.
Previous studies have demonstrated resveratrol’s specific effects on AMPAR/NMDAR activity
and expression (Quincozes-Santos, 2014), AMPK activation (Do et al., 2012), and the
transcriptional activity of PGC-1α (Lagouge et al., 2006). While some of these effects are seen in
the molecular data, not all effects are present or resemble previous studies. The few studies that
have addressed the behavioral component of resveratrol’s effects have shown similar results. For
example, using rats with streptozotocin-induced diabetes, Shmatz et al. demonstrated that a
20mg/kg dose of resveratrol could ameliorate cognitive deficits associated with diabetes (Shmatz
et al., 2009).
Some of the major differences between this study and those previously conducted are the
dosage, method of delivery, and frequency of delivery of resveratrol. In the literature, the dose of
resveratrol given to subjects varies greatly from 1mg/kg (Carbo et al., 1999) to 400mg/kg
(Lagouge et al., 2006). It is possible that the dose administered in this study was lower than
optimum.
Additionally, the route of administration differs across all studies. Some groups mix
resveratrol into the food (Baur et al., 2006), which normally corresponds to higher doses of
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resveratrol to account for loss during digestion. Other methods include subcutaneous Alzet
pumps (Robb et al., 2008), dissolving in water (Rivera, Morón, Zarzuelo, & Galisteo, 2009),
intraperitoneal injections (Simão et al., 2012), or microinjection directly into the brain region of
interest (Zhao et al., 2013). Each of these delivery systems confers a specific delivery frequency
as well. If resveratrol is dissolved into the animal’s water or mixed into their food and they are
given ad libitum access, then their dosage will be more or less continuous. The same logic holds
for the Alzet pump method. Alternatively, microinjection can only be accomplished in very
small doses over shorter periods of time. Injections can be given anywhere from multiple times
per day to one single dose, which adds yet another level of variability to this issue.
Lastly, many of these effective doses are not feasible for humans. Due to a lack of human
trials, it is not clear if resveratrol is safe if administered at the same doses. It may take up to two
grams of resveratrol each day to mimic the dose and frequency of treatment of some of these
studies. It is also clear that resveratrol has the capacity to act as a non-steroidal antiinflammatory drug and taking it alongside other NSAIDs or cancer therapeutics can increase the
risk for bleeding and other complications (Baek, Wilson, & Eling, 2002). Despite promising
evidence from animal models, it is too soon to tell the possible efficacy of human resveratrol
supplementation.
While this behavioral and physiological data are promising, further investigation must be
completed to elucidate the exact mechanisms of the behavioral effects resveratrol. Resveratrol is
a promising possible therapeutic that is currently undergoing human studies in the fields of
cancer, stroke, diabetes, and neurodegenerative diseases. If the behavioral and molecular effects
of resveratrol treatment were decoded, then physicians might be more confident in its life-
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preserving qualities and might be more willing to prescribe it before resorting to complicated and
often harmful pharmaceutical treatments.
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